Geron Corporation

1.2300-0.05 (-3.91%)

Oct 29, 4:00:01 PM EDT · NasdaqGS · GERN · USD

Upcoming Earnings

Report date

Nov 5, 2025 (in 6 days)

Key Stats

Market Cap

784.76M

P/E (TTM)

Basic EPS (TTM)

-0.13

Dividend Yield

Recent Filings

8-K

10/14/25Oct 14, 2025

8-K

8/6/25Aug 6, 2025

8-K

8/6/25Aug 6, 2025

10-Q

8/6/25Aug 6, 2025

8-K

5/27/25May 27, 2025

About

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

CEO

Ms. Michelle J. Robertson

IPO

7/31/1996

Website

https://www.geron.com

Employees

229

Sector

Healthcare

Industry

Biotechnology